A Markov model compared a hypothetical cure regimen working in 30% of patients with indefinite nucleos(t)ide analogue therapy for chronic hepatitis B. In a 50-year-old man with non-cirrhotic disease and suppressed virus, the regimen gained 0.30 quality-adjusted life years in the US and 0.57 in China. It would be cost-effective at a one-off cost below USD46,642 in the US and USD13,008 in China.
Why it is interesting: A price ceiling set for a regimen that does not yet exist, and it differs by country.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.